A clinical trial involving dulaglutide has been updated to completed status as of September 22, 2026. The study, registered as NCT07834398 and titled "Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes," is a Phase 3 trial.
According to the registry entry, the trial examined weekly GLP-1 receptor agonists in individuals with obesity who do not have diabetes. The current status listed is completed, indicating the study has finished its planned activities as of the update date.
This entry reflects a status change in the trial record rather than a report of specific outcomes or findings. No results, efficacy data, or safety conclusions are included in this update. Readers should not interpret trial completion as an indication of positive or negative results.
Further details, including any posted results, may become available through the official registry listing linked in the source material. Dulaglutide remains an approved compound, and this trial update pertains specifically to its investigation in a non-diabetic obese population under Phase 3 conditions.
For general background on dulaglutide, including its approved uses and mechanism, readers can consult the compound overview.